PD-1
Programmed cell death protein 1 (PD-1) plays an important role in subsiding immune responses and promoting self-tolerance through suppressing the activity of T cells and promoting differentiation of regulatory T cells. PD-1 is considered as an immune checkpoint and protects against autoimmune responses through both induction of apoptosis in antigen-specific T cells and inhibiting apoptosis in regulatory T cells. After PD-1 binding to its ligands, the active immune cells are inhibited. Two known ligands of PD-1 are PD-L1 and PD-L2, which belong to the B7 family. Accumulative evidence has established that the blockade of the inhibitory effects of PD-1 can elicit effective immune responses against tumor cells. PD-1 signaling pathway blockade has shown clinical responses in patients with different solid tumors and hematological malignancies[1].
[1] A Salmaninejad et al. PD-1/PD-L1 pathway: Basic biology and role in cancer immunotherapy. J Cell Physiol. 2019 Feb 19.
Axon ID | Name | Description | From price | |
---|---|---|---|---|
3433 | ARB-272572 | Potent, cellular active PD-L1 inhibitor | €150.00 | |
4247 | BMS202 hydrochloride | PD-1/PD-L1 interaction inhibitor | Recently added | €140.00 |
3694 | PD-1 Inhibitor 16 | PD-1 inhibitor | Inquire | |
2875 | PD-1 inhibitor compound 9 | Inhibitor of programmed death-1 (PD-1) protein | Inquire |